IDEAYA Biosciences, Inc. Common Stock
IDYAIDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company leverages insights from tumor genetics and tumor immune profiling to create precision medicines aimed at improving outcomes for patients with various cancers. Founded in 2015, IDEAYA is based in South San Francisco, California, and emphasizes innovative approaches in oncology treatments.
Company News
IDEAYA Biosciences announced positive Phase 2/3 trial results for darovasertib combined with crizotinib in treating metastatic uveal melanoma. The combination showed a median progression-free survival of 6.9 months versus 3.1 months for standard therapy, with a 37.1% overall response rate compared to 5.8%. The company plans to submit an FDA New D...
The global antibody optimization service market is projected to grow from USD 2.77 billion in 2024 to USD 6.07 billion by 2034, driven by advances in gene-editing technologies, AI/computational tools, and increasing biologics R&D.
Over 150 pharmaceutical companies are actively developing 170+ pipeline melanoma drugs, with promising therapies in various clinical trial stages targeting improved treatment outcomes through immunotherapies and targeted treatments.
IDEAYA Biosciences reported a Q2 2025 net loss of $0.88 per share with no revenue, but maintained strong cash reserves of $991.9 million. The company continues advancing its cancer therapy pipeline, with key clinical trials progressing in darovasertib and other oncology programs.
The melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.
